FDA Logo links to FDA home page
Center for Drug Evaluation and Research, U.S. Food and Drug AdministrationU.S. Food and Drug AdministrationCenter for Drug Evaluation and Research
  HHS Logo links to Department of Health and Human Services website

FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER

horizonal rule
Volume 2, Number 1, 2009  

Newsletter Home

In this Issue
Table of Contents
Editor's Note
Postmarket Reviews
FDA Patient Safety News
Drug Safety Communications

Newsletter Index
Newsletter Issues
Newsletter Fact Sheet
Subscribe to the Newsletter

MedWatch: The FDA Safety Information and Adverse Event Reporting Program
MedWatch 2008 Safety Alerts
Voluntary Reporting to MedWatch

Adverse Event Reporting System (AERS)

Email Us
Call Us
(1-888-463-6332) or
(301) 827-4570
This publication provides postmarketing information to healthcare professionals to enhance communication of new drug safety information, raise awareness of reported adverse events, and stimulate additional adverse event reporting.

In This Issue

Editor's Note

Postmarket Reviews

Varenicline and Bubropion
Reports of suicidality associated with use of varenicline (marketed as CHANTIX) and bupropion (marketed as ZYBAN and GENERICS)
Information for healthcare professionals on an abacavir (marketed as ZIAGEN, EPZICOM, and TRIZIVIR) hypersensitivity reaction, HLA-B*5701, and skin patch testing
Reports of serious liver injury associated with use of atomoxetine (marketed as STRATTERA)
FDA Patient Safety News
Drug Safety Communications
List of drug safety advisories posted on FDA’s Web site from September 1, 2008 through November 30, 2008, with related links
PDF Version of Current Issue
horizonal rule
horizonal rule